Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials.

@article{Hendrick1997BenefitOS,
  title={Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials.},
  author={R. Edward Hendrick and R. A. Smith and J H Rutledge and Charles R. Smart},
  journal={Journal of the National Cancer Institute. Monographs},
  year={1997},
  volume={22},
  pages={
          87-92
        }
}
Eight randomized controlled trials (RCTs) of screening mammography have been conducted involving women aged 40-49 at entry. Current data are now available from these trials at 10.5 to 18 years of follow-up (average follow-up time: 12.7 years). Meta-analysis has been performed using a Mantel-Haenszel estimator method to combine current follow-up data from the eight RCTs of mammography that included women aged 40-49 at entry, including new follow-up data presented at the NIH Consensus Development… 
View on PubMed
academic.oup.com
410 Citations
Highly Influential Citations
7
Background Citations
58
Methods Citations
11
Results Citations
7

410 Citations

Citation Type

Citation Type

Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial
Effectiveness of mammography screening in reducing breast cancer mortality in women aged 39-49 years: a meta-analysis.
TLDR
Mammography screenings are effective and generate a 17% reduction in breast cancer mortality in women 39-49 years of age, and providers should inform women in this age group about the positive and negative aspects of mammography screenings.
Randomised controlled trial of mammographic screening in women from age 40: results of screening in the first 10 years
TLDR
Results of screening in the first 10 years of a randomised trial to study the effect on breast cancer mortality of invitation to annual mammography from age 40 to 41 compared to first invitation to the 3-yearly UK national programme at age 50–52 are reported on.
Screening Mammography in Women 40 to 49 Years of Age: A Systematic Review for the American College of Physicians
Key Summary Points Meta-analyses of randomized, controlled trials demonstrate a 7% to 23% reduction in breast cancer mortality rates from screening mammography in women 40 to 49 years of age.…
Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.
  • J. Ringash
  • Medicine, Political Science
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • 2001
TLDR
Current evidence regarding the effectiveness of screening mammography does not suggest the inclusion of the manoeuvre in, or its exclusion from, the periodic health examination of women aged 40-49 years at average risk of breast cancer (grade C recommendation).
The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization.
TLDR
M mammographic screening can reduce mortality from breast carcinoma in women ages < 50 years if high quality mammography is used and an 18-month interscreening interval is strictly adhered to.
The Canadian National Breast Screening Study-1: Breast Cancer Mortality after 11 to 16 Years of Follow-up: A Randomized Screening Trial of Mammography in Women Age 40 to 49 Years
TLDR
The CNBSS suggests that screening 40- to 49-year-old women is unlikely to reduce breast cancer by 20% or more, and the conduct and interpretation of the breast physical examination would be unbiased by knowledge of whether mammography would follow.
Preventive health care , 2001 update : screening mammography among women aged 40 – 49 years at average risk of breast cancer
TLDR
Current evidence regarding the effectiveness of screening mammography does not suggest the inclusion of the manoeuvre in, or its exclusion from, the periodic health examination of women aged 40–49 years at average risk of breast cancer (grade C recommendation).
Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures
TLDR
This analysis based on surrogate outcome measures suggests that a reduction in breast cancer mortality may be observed in this trial, however, a number of assumptions have been necessary and firm conclusions must await the analysis of observed mortality from breast cancer.
Breast screening policy: are we heading in the right direction?
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
The Stockholm Mammographic Screening Trial: Risks and benefits in age group 40-49 years.
TLDR
New data on breast cancer mortality for women under age 50 from the Stockholm Mammographic Screening Trial is presented, as well as a review of some side effects associated with screening in this age group.
Breast-cancer screening with mammography in women aged 40–49 years
TLDR
It is likely that mammographic screening of women aged 40 to 49 can reduce subsequent mortality from breast cancer, and studies on tumour progression indicate that to obtain substantial benefit it is probably necessary to screen every 12 to 18 months, with 2-view mammography and double reading of films.
Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit.
  • K. Kerlikowske
  • Medicine
    Journal of the National Cancer Institute. Monographs
  • 1997
TLDR
The absolute benefit of screening women aged 40 to 49 years is small and there is concern that the harms are substantial, the focus should be to help these women make informed decisions about screening mammography by educating them of their true risk of breast cancer and the potential benefits and risks of screening.
Breast cancer screening outcomes in women ages 40-49: clinical experience with service screening using modern mammography.
  • E. Sickles
  • Medicine
    Journal of the National Cancer Institute. Monographs
  • 1997
TLDR
The use of surrogate measures of screening efficacy (tumor size, lymph node status, cancer stage), readily derived from modern service screening programs, demonstrates how the improved mammography of the 1990s should produce a greater degree of mortality reduction among women ages 40-49 than that already demonstrated in the RCTs.
Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan.
  • S. Shapiro
  • Medicine
    Journal of the National Cancer Institute. Monographs
  • 1997
TLDR
The findings of the first breast cancer screening trial are summarized, which found that to a large extent the difference among the 40-49-year-olds occurred in the subgroup with breast cancer diagnosed after these women had passed their 50th birthday, and utility of screening women in their forties is questionable.
Breast cancer screening with mammography: overview of Swedish randomised trials
Quantitative Interpretation of Age-Specific Mortality Reductions From the Swedish Breast Cancer-Screening Trials
TLDR
Results from the Swedish randomized breast cancer-screening trials should be seen as more favorable regarding the effect of mammographic screening in reducing breast cancer mortality for women aged 50-69 years than was estimated earlier.
Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years.
TLDR
Screening with yearly mammography and physical examination of the breasts detected considerably more node-negative, small tumours than usual care, but it had no impact on the rate of death from breast cancer up to 7 years' follow-up from entry.
Report of the International Workshop on Screening for Breast Cancer.
BACKGROUND Over the past 30 years, eight major randomized controlled trials of breast cancer screening--with mammography and/or clinical breast examination--have been conducted. Results from several…
Mammography outcomes in a practice setting by age: prognostic factors, sensitivity, and positive biopsy rate.
TLDR
Modern mammography in a community practice setting can successfully detect breast cancers with favorable prognostic factors and achieve constant sensitivity and acceptable PBRs in all women over 40, and the data suggest that many of the large differences seen by inappropriately dividing data at age 50 decrease or disappear when analysis is performed by decade.
...
1
2
3
4
5
...